Avinger Inc.
| NASDAQ: AVGR | Healthcare / Medical Devices & Instruments / USA |
| 2.85 | -0.1600 | -5.32% | Vol 33.31K | 1Y Perf 131.54% |
| Nov 29th, 2023 16:00 DELAYED |
| BID | 2.83 | ASK | 2.85 | ||
| Open | 3.01 | Previous Close | 3.01 | ||
| Pre-Market | - | After-Market | 2.85 | ||
| - - | 0.00 -0.02% |
| Target Price | 7.50 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 163.16 | Finscreener Ranking | ★★+ 47.95 | |
| Insiders Trans % 3/6/12 mo. | -/-/-100 | Value Ranking | ★ 41.89 | |
| Insiders Value % 3/6/12 mo. | -/-/-100 | Growth Ranking | ★ 37.44 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/-100 | Income Ranking | — - | |
| Price Range Ratio 52W % | -0.70 | Earnings Rating | Strong Buy | |
| Market Cap | 3.90M | Earnings Date | 26th Oct 2023 | |
| Alpha | -0.04 | Standard Deviation | 0.42 | |
| Beta | 1.42 |
Today's Price Range 2.783.01 | 52W Range 3.0024.30 | 5 Year PE Ratio Range -0.6000-0.1000 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -6.25% | ||
| 1 Month | -28.39% | ||
| 3 Months | 465.45% | ||
| 6 Months | 407.48% | ||
| 1 Year | 131.54% | ||
| 3 Years | 872.70% | ||
| 5 Years | -8.06% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -3 546.54 | |||
ROE last 12 Months | -379.44 | |||
ROA (5Y Avg) | -36.14 | |||
ROA last 12 Months | -98.96 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -109.62 | |||
Return on invested Capital Q | -22.75 | |||
Return on invested Capital Y | -21.55 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 4.60 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.20 | ||||
| 1.80 | ||||
| 1.51 | ||||
| - | ||||
| -0.60 | ||||
| -3.17 | ||||
| 1.80 | ||||
| 0.67 | ||||
| 7.70M | ||||
| Forward PE | -1.39 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 2.70 | ||||
| 3.50 | ||||
| 0.75 | ||||
| 3.26 | ||||
| -9.70 | ||||
| Leverage Ratio | 4.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 30.90 | ||||
| -192.70 | ||||
| -189.30 | ||||
| -295.30 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 6.27M | ||||
| 0.84 | ||||
| 5.75 | ||||
| -6.48 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2023 | -2.85 | -2.92 | -2.46 |
| Q02 2023 | -7.35 | -8.85 | -20.41 |
| Q01 2023 | -7.35 | -10.64 | -44.76 |
| Q04 2022 | - | -10.49 | - |
| Q03 2022 | - | -11.54 | - |
| Q02 2022 | -16.34 | -14.09 | 13.77 |
| Q01 2022 | -1.21 | -2.33 | -92.56 |
| Q04 2021 | -1.26 | -1.26 | 0.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2023 QR | 0.64 | -74.90 | Negative |
| 12/2023 FY | -3.59 | 81.86 | Positive |
| 3/2024 QR | -3.20 | -12.28 | Negative |
| 12/2024 FY | -2.26 | 74.02 | Positive |
| Next Report Date | - |
| Estimated EPS Next Report | -2.85 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 33.31K |
| Shares Outstanding | 1.37K |
| Shares Float | 1.27M |
| Trades Count | 384 |
| Dollar Volume | 95.85K |
| Avg. Volume | 636.50K |
| Avg. Weekly Volume | 17.20K |
| Avg. Monthly Volume | 25.64K |
| Avg. Quarterly Volume | 1.87M |
Avinger Inc. (NASDAQ: AVGR) stock closed at 2.85 per share at the end of the most recent trading day (a -5.32% change compared to the prior day closing price) with a volume of 33.31K shares and market capitalization of 3.90M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 81 people. Avinger Inc. CEO is Jeffrey M. Soinski.
The one-year performance of Avinger Inc. stock is 131.54%, while year-to-date (YTD) performance is 162.67%. AVGR stock has a five-year performance of -8.06%. Its 52-week range is between 3 and 24.3, which gives AVGR stock a 52-week price range ratio of -0.70%
Avinger Inc. currently has a PE ratio of -0.20, a price-to-book (PB) ratio of 1.80, a price-to-sale (PS) ratio of 1.51, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -98.96%, a ROC of -109.62% and a ROE of -379.44%. The company’s profit margin is -%, its EBITDA margin is -189.30%, and its revenue ttm is $6.27 Million , which makes it $0.84 revenue per share.
Of the last four earnings reports from Avinger Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-2.85 for the next earnings report. Avinger Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Avinger Inc. is Strong Buy (1), with a target price of $7.5, which is +163.16% compared to the current price. The earnings rating for Avinger Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Avinger Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Avinger Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 21.54, ATR14 : 0.34, CCI20 : -112.49, Chaikin Money Flow : -0.34, MACD : -0.36, Money Flow Index : 29.32, ROC : -14.49, RSI : 38.07, STOCH (14,3) : 1.28, STOCH RSI : 0.37, UO : 22.17, Williams %R : -98.72), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Avinger Inc. in the last 12-months were:
Avinger Inc.
Avinger Inc is a United States-based medical device company. It is engaged in designing, manufacturing and selling image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease (PAD). The products offered by the firm include Lightbox imaging console, the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO) and Pantheris, image-guided atherectomy device which is designed to allow physicians to precisely remove arterial plaque in PAD patients. It manufactures and sells products in the United States and internationally of which it generates the majority of the revenue from the sales made in the United States.
CEO: Jeffrey M. Soinski
Telephone: +1 650 241-7900
Address: 400 Chesapeake Drive, Redwood City 94063, CA, US
Number of employees: 81
